MADRID – New research presented at the ESC Congress 2025 highlights the effectiveness of mavacamten in treating nonobstructive hypertrophic cardiomyopathy (nHCM). The ODYSSEY-HCM trial, unveiled during the HOT LINE 2 session and simultaneously published in the New England Journal of Medicine [[1]], showcases the drug’s potential to improve cardiac function in patients with nHCM.

Hypertrophic cardiomyopathy (HCM) is a condition in which the heart muscle becomes abnormally thick, making it harder for the heart to pump blood. In nonobstructive HCM, this thickening does not significantly block blood flow out of the heart. Mavacamten is a selective cardiac myosin inhibitor that reduces the excessive contractility characteristic of HCM.

Key Findings from the ODYSSEY-HCM Trial

The ODYSSEY-HCM trial evaluated the use of mavacamten in symptomatic patients with nHCM. the study demonstrated significant improvements in several key areas, including:

• Improved exercise capacity
• Reduced heart muscle thickness
• Enhanced quality of life

“Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy.”

Further insights from the trial will be presented in two additional sessions at the ESC Congress 2025. One session will focus on cardiac biomarkers in nHCM patients treated with mavacamten [[3]], while the other will explore echocardiographic changes observed in these patients [[4]].

Expert Commentary

“these findings represent a significant step forward in the treatment of nonobstructive HCM,” said Professor Desai, a lead investigator in the trial. “mavacamten offers a targeted approach to address the underlying mechanisms of the disease, potentially improving the lives of many patients.” Professor Desai reports consultant and research agreements with Bristol Myers Squibb,Edgewise,viz AI,Tenaya and Cytokinetics.

The trial was funded by Bristol Myers Squibb.